Elite in Prostate Cancer

Dr. Curtis J. Dunshee

Urology
Arizona Urology Specialists PLLC
2530 E Southern Ave, 
Mesa, AZ 
Accepting New Patients
Offers Telehealth
Elite in Prostate Cancer
Arizona Urology Specialists PLLC
2530 E Southern Ave, 
Mesa, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Curtis Dunshee is an Urologist in Mesa, Arizona. Dr. Dunshee is rated as an Elite provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Bladder Cancer, Ureteroscopy, and Prostatectomy. Dr. Dunshee is currently accepting new patients.

His clinical research consists of co-authoring 22 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 22 articles and participated in 4 clinical trials in the study of Prostate Cancer.

Specialties
Urology
Licenses
Urology in AZ
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Dominion National
  • MEDICARE PDP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VibrantRx
  • MEDICARE PDP
  • OTHER MEDICARE
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

ARIZONA UROLOGY SPECIALISTS PLLC
2530 E Southern Ave, Mesa, AZ 85204
Other Locations
ARIZONA UROLOGY SPECIALISTS PLLC
2260 W Orange Grove Rd, Tucson, AZ 85741

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 1/2a Pilot Study of Intravesical TSD-001 for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
A Phase 1/2a Pilot Study of Intravesical TSD-001 for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: June 27, 2025
Intervention Type: Drug
Study Drug: Paclitaxel
Study Phase: Phase 1/Phase 2
A Prospective, Multicenter, Double Blind, Randomized, Clinical Study to Evaluate the Safety and Efficacy of the Optilume™ BPH Catheter System in Men With Symptomatic BPH
A Prospective, Multicenter, Double Blind, Randomized, Clinical Study to Evaluate the Safety and Efficacy of the Optilume™ BPH Catheter System in Men With Symptomatic BPH
Enrollment Status: Active_not_recruiting
Publish Date: April 09, 2025
Intervention Type: Device
Study Phase: Not Applicable
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 31, 2024
Intervention Type: Drug
Study Drug: Fuzuloparib+Abiraterone Acetate+Prednisone
Study Phase: Phase 3
A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib in Patients With Metastatic Castration-resistant Prostate Cancer Following Standard of Care Treatment
A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib in Patients With Metastatic Castration-resistant Prostate Cancer Following Standard of Care Treatment
Enrollment Status: Completed
Publish Date: October 10, 2024
Intervention Type: Drug
Study Drugs: LAE001, Prednisone, Afuresertib
Study Phase: Phase 1/Phase 2
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
Enrollment Status: Completed
Publish Date: July 18, 2023
Intervention Type: Drug
Study Drugs: Gepotidacin, Nitrofurantoin
Study Phase: Phase 3
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Enrollment Status: Completed
Publish Date: September 01, 2022
Intervention Type: Other
A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BHR-200 (0.36% Transdermal Estradiol Gel) for the Maintenance of Testosterone Suppression in Men With Advanced Androgen-Sensitive Prostate Cancer
A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BHR-200 (0.36% Transdermal Estradiol Gel) for the Maintenance of Testosterone Suppression in Men With Advanced Androgen-Sensitive Prostate Cancer
Enrollment Status: Terminated
Publish Date: March 31, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

22 Total Publications

Corrigendum to "Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study" [Eur J Cancer 213 (December) (2024) 115078].
Corrigendum to "Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study" [Eur J Cancer 213 (December) (2024) 115078].
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 19, 2025
Similar Doctors
Distinguished in Prostate Cancer
Dr. Mitchell R. Humphreys
Urology
Distinguished in Prostate Cancer
Dr. Mitchell R. Humphreys
Urology

Mayo Clinic Arizona

5701 E Mayo Blvd, 
Phoenix, AZ 
 (21.0 miles away)
480-342-4200
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mitchell Humphreys is an Urologist in Phoenix, Arizona. Dr. Humphreys is rated as an Elite provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Enlarged Prostate (BPH), Kidney Stones, Prostate Cancer, Ureteroscopy, and Lithotripsy. Dr. Humphreys is currently accepting new patients.

Distinguished in Prostate Cancer
Dr. Paul E. Andrews
Urology
Distinguished in Prostate Cancer
Dr. Paul E. Andrews
Urology

Mayo Clinic Arizona

5779 E Mayo Blvd, Speciality Building, 
Phoenix, AZ 
 (21.1 miles away)
480-301-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Paul Andrews is an Urologist in Phoenix, Arizona. Dr. Andrews is rated as a Distinguished provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Bladder Cancer, Nephrectomy, and Reconstructive Urology Surgery. Dr. Andrews is currently accepting new patients.

Distinguished in Prostate Cancer
Dr. Bernard M. Gburek
Urology
Distinguished in Prostate Cancer
Dr. Bernard M. Gburek
Urology

Arizona Urology Specialists PLLC

7340 E Thomas Rd, 
Scottsdale, AZ 
 (10.3 miles away)
602-557-0060
Languages Spoken:
English, French
See accepted insurances
Accepting New Patients
Offers Telehealth

Bernard Gburek is an Urologist in Scottsdale, Arizona. Dr. Gburek is rated as a Distinguished provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Familial Prostate Cancer, Prostate Cancer, Obstructive Uropathy, Ureteroscopy, and Vasectomy. Dr. Gburek is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dunshee's expertise for a condition
ConditionClose
View All 29 Advanced Conditions
View All 21 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile